Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418743
Status:
UNKNOWN
Last Update Posted:
2010-03-09
First Post:
2007-01-04
Brief Title:
Second-line Treatment in Patients With Small Cell Lung Cancer SCLC
Sponsor:
Groupe Francais De Pneumo-Cancerologie
Organization:
Groupe Francais De Pneumo-Cancerologie
Study Overview
Official Title:
A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer SCLC Comparing Oral Combination Chemotherapy CCNU Cyclophosphamide Etoposide With Intravenous Association Chemotherapy
Status:
UNKNOWN
Status Verified Date:
2010-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy
Detailed Description:
Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None